Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant (IMVT) insider filing: the Chief Medical Officer reported selling 2,595 shares on October 22, 2025 at a weighted average price of $19.03 (range $19.03–$19.20). The sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting and settlement of RSUs.
After the transaction, the reporting person beneficially owns 217,958 shares. Footnotes note that 6,250 of a previously granted 100,000 RSUs vested on October 17, 2025.
Immunovant, Inc. (IMVT) disclosed an insider transaction by its Chief Technology Officer, Jay Stout. On 10/22/2025, he sold 2,520 shares of common stock at a weighted average price of $19.03 per share, with trades executed between $19.03–$19.23. The filing states this was a mandated “sell to cover” to satisfy tax withholding arising from the vesting and settlement of 6,250 RSUs on 10/17/2025, part of a 100,000 RSU grant awarded on 04/17/2023, and was not a discretionary transaction.
Following the sale, Stout beneficially owned 200,814 shares, held directly.
Insider sale to cover taxes: The Chief Medical Officer, Michael Geffner, sold 1,272 shares of Immunovant common stock on 10/08/2025 as a sell-to-cover to satisfy tax withholding tied to vested restricted stock units. The weighted average sale price was $16.30 per share (individual trades ranged $16.06–$16.48).
Geffner was granted 54,978 RSUs on 4/2/2024; 3,436 of those RSUs vested on 10/2/2025. After the reported sale, the reporting person beneficially owned 220,553 shares. The filing states the sale was mandated by the issuer's sell-to-cover tax election and not a discretionary transaction.
On 10/08/2025, Chief Technology Officer Jay S. Stout reported the sale of 1,585 shares of Immunovant, Inc. (IMVT) common stock at a weighted average price of $16.3 per share. The shares sold were from the vesting and settlement of restricted stock units granted on 04/02/2024; 3,436 RSUs vested on 10/02/2025. The sale was executed as a mandatory "sell to cover" to satisfy tax withholding and was not a discretionary sale by the reporting person. After the reported transactions, the reporting person beneficially owned 203,334 shares.
Immunovant, Inc. reported that it issued a press release on September 3, 2025 providing an update on its Graves’ Disease development program. The press release is included as an exhibit and is incorporated by reference.
The company also posted an investor presentation on its website covering an update on its Graves’ Disease proof-of-concept study and plans to host a conference call and webcast at 4:30 p.m. E.D.T. to discuss remission data from the trial. The presentation used for this call is filed as a separate exhibit.
Immunovant, Inc. reported voting results from its 2025 Annual Meeting of Stockholders held on August 27, 2025. A total of 165,885,480 shares of common stock and Series A preferred stock were represented, about 97% of the shares entitled to vote, indicating very high participation.
Stockholders elected Jacob Bauer, Douglas Hughes and Robert Susman to the Board of Directors until the 2026 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2026, with 165,422,634 votes for, 7,237 against and 455,609 abstaining.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of Immunovant’s named executive officers, with 158,995,232 votes for, 1,244,731 against, 4,437 abstaining and 5,641,080 broker non-votes.
Immunovant is a clinical-stage immunology company advancing two anti-FcRn antibodies, IMVT-1402 and batoclimab. For the quarter ended June 30, 2025 the company reported a net loss of $120.6 million versus $87.2 million a year earlier, driven by higher research and development ($101.2 million versus $75.5 million) and increased general and administrative expense ($26.0 million versus $18.8 million). Cash and cash equivalents totaled $598.9 million at quarter end, down from $714.0 million three months earlier, and cash used in operations was $117.4 million.
The company has initiated multiple potentially registrational IMVT-1402 trials across Graves disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sj f6grens disease and a CLE proof-of-concept study, and expects a Graves disease readout in 2027. Batoclimab Phase 3 top-line results in thyroid eye disease are expected in the second half of 2025. Contractual commitments include an estimated $43.1 million remaining minimum purchase obligation to Samsung and potential milestone payments under the HanAll license up to $420.0 million (after $32.5 million previously paid).
Immunovant, Inc. furnished an update on its business by issuing a press release with financial results for its fiscal first quarter ended June 30, 2025. The company reported these results publicly on August 11, 2025, and attached the press release as Exhibit 99.1.
The disclosure is made under the Results of Operations and Financial Condition section and is treated as furnished rather than filed, which limits certain legal liabilities. The report is signed on behalf of Immunovant by Chief Financial Officer Tiago Girao on August 11, 2025.